drugset / Trial / NCT05131711
Combination of Stereotactic Radiosurgery and Enhanced Immunotherapy for Recurrent Glioblastomas(inSituVac2)(CSREIG)
RandomizedParallel-groupOpen-labelTreatment
Summary
The study will investigate combined stereotactic radiosurgery and enhanced immunotherapy for recurrent glioblastomas. Immune adjuvants will be injected intratumorally and systemically to induce antitumor-specific immunity after radiation induced immunological tumor cell death (ICD). With radiation, tumor cells release tumor antigens that are captured by antigen presenting dendritic cells. Immune adjuvants promote the presentation of tumor antigens and the priming of antitumor T lymphocytes. The combined treatment induces and amplifies the specific antitumor immunity in patients with recurrent glioblastomas, prolonging survivals of patients.
Timeline
- Start
- 2021-11-16
- Primary completion
- 2022-11-16
- Completion
- 2023-11-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MnCl2 | Unknown | — | Other |
| Subject | Sapylin | Other / unclassified | — | Other |
| Subject | sargramostim | Protein / enzyme biologic | — | Other |